Behzad Aghazadeh

Insider · Director and 10% owner and Other role · SCTX

Behzad Aghazadeh files insider transactions with the SEC as a director and 10% owner and other role of Scribe Therapeutics (SCTX). We hold 2 disclosed purchases and sales filed since 12 October 2017, 2 of them in the last 90 days.

Files forSCTX
Disclosed buys and sells2 in all, 2 in the last 90 days
Last disclosure28 July 2026

Positions held

6 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 23 July 2026 — 28 July 2026Director and 10% owner and Other role · Scribe Therapeutics (SCTX)4 Form 4 lines · source: SEC Form 4
Filed 12 June 2026 — 12 June 2026Director and 10% owner and Other role · Whitehawk Therapeutics (WHWK)1 Form 4 line · source: SEC Form 4
Filed 26 August 2021 — 28 February 2025Director and 10% owner and Other role · Aadi Bioscience (AADI)4 Form 4 lines · source: SEC Form 4
Filed 22 November 2021 — 13 September 202310% owner · CymaBay Therapeutics (CBAY)7 Form 4 lines · source: SEC Form 4
Filed 24 August 2017 — 23 October 2020Director and TenPercentOwnerOther · Immunomedics (IMMU)23 Form 4 lines · source: SEC Form 4
Filed 11 June 2018 — 23 July 201910% owner · Mirati Therapeutics (MRTX)7 Form 4 lines · source: SEC Form 4

Everything they disclosed

46 entries, newest first — one per disclosure report, one per Form 4 line

▲ bought on the open market 2,333,333 shares of Scribe TherapeuticsSEC Form 428 July 2026Common Stock, par value $0.0001 per share · traded 24 July 2026 · filed 28 July 2026
▲ bought on the open market 50,000 shares of Scribe TherapeuticsSEC Form 428 July 2026Common Stock, par value $0.0001 per share · traded 24 July 2026 · filed 28 July 2026
▲ bought on the open market 7,905 shares of Scribe TherapeuticsSEC Form 428 July 2026Common Stock, par value $0.0001 per share · traded 28 July 2026 · filed 28 July 2026
was granted 14,725 shares of Scribe Therapeutics (a derivative holding)SEC Form 427 July 2026Stock Option (Right to Buy) · traded 23 July 2026 · filed 27 July 2026
was granted 38,040 shares of Whitehawk Therapeutics (a derivative holding)SEC Form 415 June 2026Stock Option (right to buy) · traded 12 June 2026 · filed 15 June 2026
was granted 8,333,000 shares of Aadi Bioscience (a derivative holding)SEC Form 44 March 2025Pre-funded Warrant (right to buy) · traded 28 February 2025 · filed 4 March 2025
▼ sold on the open market 1,500 shares of CymaBay Therapeutics (a derivative holding)SEC Form 414 September 2023Put Option (obligation to buy) · traded 12 September 2023 · filed 14 September 2023
▼ sold on the open market 300 shares of CymaBay Therapeutics (a derivative holding)SEC Form 414 September 2023Put Option (obligation to buy) · traded 12 September 2023 · filed 14 September 2023
▼ sold on the open market 250 shares of CymaBay Therapeutics (a derivative holding)SEC Form 414 September 2023Put Option (obligation to buy) · traded 13 September 2023 · filed 14 September 2023
▼ sold on the open market 950 shares of CymaBay Therapeutics (a derivative holding)SEC Form 414 September 2023Put Option (obligation to buy) · traded 13 September 2023 · filed 14 September 2023
▲ bought on the open market 583,771 shares of CymaBay Therapeutics (a derivative holding)SEC Form 414 September 2023Pre-funded Warrant (right to buy) · traded 12 September 2023 · filed 14 September 2023
was granted 28,255 shares of Aadi Bioscience (a derivative holding)SEC Form 420 June 2023Stock Option (right to buy) · traded 15 June 2023 · filed 20 June 2023
▲ bought on the open market 2,142,857 shares of CymaBay Therapeutics (a derivative holding)SEC Form 430 January 2023Pre-funded Warrant (right to buy) · traded 26 January 2023 · filed 30 January 2023
▲ bought on the open market 2,500,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 423 November 2021Pre-funded Warrant (right to buy) · traded 22 November 2021 · filed 23 November 2021
was granted 17,549 shares of Aadi Bioscience (a derivative holding)SEC Form 430 August 2021Stock option (right to buy) · traded 27 August 2021 · filed 30 August 2021
was granted 1,911,752 shares of Aadi BioscienceSEC Form 430 August 2021"Common Stock, $0.0001 par value per share (""Common Stock"")" · traded 26 August 2021 · filed 30 August 2021
returned to the issuer 202,614 shares of Immunomedics (a derivative holding)SEC Form 423 October 2020Stock Option (Right to Buy) · traded 23 October 2020 · filed 23 October 2020
returned to the issuer 103,718 shares of Immunomedics (a derivative holding)SEC Form 423 October 2020Restricted Stock Unit · traded 23 October 2020 · filed 23 October 2020
returned to the issuer 13,516 shares of ImmunomedicsSEC Form 423 October 2020Common Stock · traded 23 October 2020 · filed 23 October 2020
returned to the issuer 26,250,000 shares of ImmunomedicsSEC Form 423 October 2020Common Stock · traded 23 October 2020 · filed 23 October 2020
▲ bought on the open market 1,750,000 shares of ImmunomedicsSEC Form 41 May 2020Common Stock, $0.01 par value per share · traded 1 May 2020 · filed 1 May 2020
was granted 100,000 shares of ImmunomedicsSEC Form 420 March 2020Common Stock, $0.01 par value per share · traded 20 March 2020 · filed 20 March 2020
▲ bought on the open market 2,000,000 shares of ImmunomedicsSEC Form 49 December 2019"Common Stock, $0.01 par value per share (""Common Stock"")" · traded 5 December 2019 · filed 9 December 2019
▼ sold on the open market 62,500 shares of Mirati TherapeuticsSEC Form 425 July 2019Common Stock, $0.001 par value per share · traded 23 July 2019 · filed 25 July 2019
was granted 17,077 shares of Immunomedics (a derivative holding)SEC Form 411 June 2019Stock Option (right to buy) · traded 7 June 2019 · filed 11 June 2019
was granted 9,667 shares of ImmunomedicsSEC Form 411 June 2019Common Stock, $0.01 par value per share (''Common Stock'') · traded 7 June 2019 · filed 11 June 2019
▼ sold on the open market 125,000 shares of Mirati TherapeuticsSEC Form 420 March 2019"Common Stock, $0.001 par value per share (""Common Stock"")" · traded 18 March 2019 · filed 20 March 2019
▼ sold on the open market 100,000 shares of Mirati TherapeuticsSEC Form 420 March 2019Common Stock · traded 19 March 2019 · filed 20 March 2019
▼ sold on the open market 23,781 shares of Mirati TherapeuticsSEC Form 420 March 2019Common Stock · traded 20 March 2019 · filed 20 March 2019
▼ sold on the open market 686,820 shares of Mirati TherapeuticsSEC Form 421 February 2019Common Stock, $0.001 par value per share · traded 20 February 2019 · filed 21 February 2019
was granted 6,497 shares of Immunomedics (a derivative holding)SEC Form 418 September 2018Stock Options (right to buy) · traded 2 April 2018 · filed 18 September 2018
was granted 3,849 shares of ImmunomedicsSEC Form 418 September 2018Common Stock, $0.01 par value per share · traded 2 April 2018 · filed 18 September 2018
▲ bought on the open market 575,000 shares of ImmunomedicsSEC Form 415 June 2018Common Stock, $0.01 par value per share · traded 15 June 2018 · filed 15 June 2018
▲ bought on the open market 400,000 shares of Mirati TherapeuticsSEC Form 412 June 2018"Common Stock, $0.001 par value per share (""Common Stock"")" · traded 11 June 2018 · filed 12 June 2018
▲ bought on the open market 63,235 shares of Mirati Therapeutics (a derivative holding)SEC Form 412 June 2018Warrant (right to buy) · traded 11 June 2018 · filed 12 June 2018
exercised in-the-money options over 875,000 shares of ImmunomedicsSEC Form 416 February 2018"Common Stock, $0.01 par value per share (the ""Common Stock"")" · traded 16 February 2018 · filed 16 February 2018
exercised in-the-money options over 5,000 shares of Immunomedics (a derivative holding)SEC Form 416 February 2018Call Option (right to buy) · traded 16 February 2018 · filed 16 February 2018
filed a transaction coded E in 5,000 shares of Immunomedics (a derivative holding)SEC Form 416 February 2018Put Option (obligation to buy) · traded 16 February 2018 · filed 16 February 2018
exercised in-the-money options over 2,500 shares of Immunomedics (a derivative holding)SEC Form 416 February 2018Call Option (right to buy) · traded 16 February 2018 · filed 16 February 2018
filed a transaction coded E in 2,500 shares of Immunomedics (a derivative holding)SEC Form 416 February 2018Put Option (obligation to buy) · traded 16 February 2018 · filed 16 February 2018
exercised in-the-money options over 1,250 shares of Immunomedics (a derivative holding)SEC Form 416 February 2018Call Option (right to buy) · traded 16 February 2018 · filed 16 February 2018
filed a transaction coded E in 1,250 shares of Immunomedics (a derivative holding)SEC Form 416 February 2018Put Option (obligation to buy) · traded 16 February 2018 · filed 16 February 2018
▲ bought on the open market 1,150,000 shares of ImmunomedicsSEC Form 415 November 2017"Common Stock, $0.01 par value per share (the ""Common Stock"")" · traded 14 November 2017 · filed 15 November 2017
▲ bought on the open market 175,000 shares of ImmunomedicsSEC Form 415 November 2017Common Stock · traded 15 November 2017 · filed 15 November 2017
converted 4,251,386 shares of ImmunomedicsSEC Form 412 October 2017"Common Stock, $0.01 par value per share (the ""Common Stock"")" · traded 24 August 2017 · filed 12 October 2017
converted 184,000 shares of Immunomedics (a derivative holding)SEC Form 412 October 2017Series A-1 Convertible Preferred Stock · traded 24 August 2017 · filed 12 October 2017

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.